LXEO — Lexeo Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2023-11-03.
Performance
Technicals
Others in Healthcare
Measured signals that fired on LXEO
| date | signal | measured base rate |
|---|---|---|
| 2026-08-19 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-08-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-01 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
| 2026-06-03 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-03-23 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-18 | Tamayo Louis Edward Chief Financial Officer | Open-market sale | 4.1K | 4.91 | 20.2K |
| 2026-08-18 | Townsend Richard Nolan Chief Executive Officer | Open-market sale | 3.3K | 4.95 | 16.6K |
| 2026-08-18 | Otero Jose Manuel Chief Operating Officer | Open-market sale | 1.3K | 4.96 | 6.5K |
| 2026-07-01 | Townsend Richard Nolan Chief Executive Officer | Open-market sale | 25.9K | 4.48 | 116.2K |
| 2026-07-01 | Bhalla Narinder Pal Chief Medical Officer | Open-market sale | 22.3K | 4.42 | 98.6K |
| 2026-07-01 | Otero Jose Manuel Chief Operating Officer | Open-market sale | 4.7K | 4.48 | 20.9K |
| 2026-07-01 | Tamayo Louis Edward Chief Financial Officer | Open-market sale | 4.6K | 4.49 | 20.8K |
| 2026-06-29 | Townsend Richard Nolan Chief Executive Officer | Grant or award | 67.0K | 0.00 | 0 |
| 2026-06-29 | Tamayo Louis Edward Chief Financial Officer | Grant or award | 12.0K | 0.00 | 0 |
| 2026-06-29 | Otero Jose Manuel Chief Operating Officer | Grant or award | 12.1K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Paradigm Biocapital Advisors LP | 35.5M | 6.2M |
| BlackRock, Inc. | 29.3M | 5.1M |
| Affinity Asset Advisors, LLC | 29.0M | 5.1M |
| RA CAPITAL MANAGEMENT, L.P. | 28.7M | 5.0M |
| JANUS HENDERSON GROUP PLC | 28.5M | 5.0M |
| Vestal Point Capital, LP | 25.7M | 4.5M |
| Frazier Life Sciences Management, L.P. | 25.4M | 4.4M |
| CITADEL ADVISORS LLC | 22.0M | 3.8M |
| ORBIMED ADVISORS LLC | 20.7M | 3.6M |
| STATE STREET CORP | 20.5M | 3.6M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Lexeo Therapeutics, Inc. (LXEO) filed form 8-K · 2026-08-12 · SEC EDGAR
Ask the AI about LXEO
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →